Skip to main content

Advertisement

Table 2 Change from baseline at week 24 and week 52 for patient-reported outcomes

From: Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

PRO measurea (95% CI)   Week 24    Week 52  
  MTX (N = 210) Baricitinib 4 mg (N = 159) Baricitinib 4 mg + MTX (N = 215) MTX (N = 210) Baricitinib 4 mg (N = 159) Baricitinib 4 mg + MTX (N = 215)
Physical Function (HAQ-DI) − 0.74 (− 0.83, − 0.66) − 1.04 (− 1.14, − 0.95)*** − 1.03 (− 1.11, − 0.95)*** − 0.71 (− 0.79, − 0.62) − 0.99 (− 1.08, − 0.89)*** − 1.06 (− 1.14, − 0.97)***
Patient’s Global Assessment of Disease Activity (PtGA) − 31 (− 34, − 27) − 41 (− 45, − 38)*** − 40 (− 43, − 37)*** − 29 (− 32, − 26) − 40 (− 44, − 37)*** − 43 (− 46, − 39)***
Patient’s assessment of pain − 30 (− 33, − 27) − 41 (− 45 − 37)*** − 41 (− 44, − 38)*** − 31 (− 34, − 27) − 40 (− 44, − 37)*** − 43 (− 47, − 40)***
FACIT-F 8.9 (7.6, 10.1) 13.3 (11.8, 14.7)*** 12.2 (11.0, 13.5)*** 8.9 (7.6, 10.2) 11.7 (10.2, 13.1)** 12.6 (11.4, 13.9)***
MJS Duration, median change from baseline − 35.0 (− 55.0, − 25.0) − 50.0 (− 60.0, − 30.0) − 59.0 (− 85.0, − 40.0)** − 40.0 (− 55.0, − 30.0) − 55.0 (− 60.0, − 40.0) − 60.0 (− 80.0, − 50.0)**
Worst Joint Pain NRS − 2.8 (− 3.2, − 2.5) − 4.0 (− 4.3, − 3.6) *** − 4.0 (− 4.3, − 3.7)*** − 3.0 (− 3.4, − 2.7) − 3.9 (− 4.3, − 3.6)*** − 4.1 (− 4.4, − 3.8)***
Worst Tiredness NRS − 2.1 (− 2.5, − 1.8) − 3.1 (− 3.5, − 2.7)*** − 3.0 (− 3.3, − 2.7)*** − 2.2 (− 2.5, − 1.8) − 3.0 (− 3.4, − 2.6)** − 2.9 (− 3.3, − 2.6)**
EuroQol-5 Dimensions (EQ-5D)
 Health State Index Score, UK algorithm 0.200 (0.173, 0.227) 0.288 (0.257, 0.318)*** 0.288 (0.261, 0.315)*** 0.191 (0.161, 0.221) 0.272 (0.239, 0.306)*** 0.273 (0.244, 0.303)***
 US algorithm 0.138 (0.119, 0.158) 0.199 (0.177, 0.221) *** 0.199 (0.179, 0.218) *** 0.133 (0.111, 0.154) 0.187 (0.163, 0.211)*** 0.189 (0.168, 0.210)***
 Self-perceived health score 15 (12, 18) 24 (20, 27)*** 22 (18, 25)** 14 (11, 18) 25 (21, 28)*** 25 (22, 28)***
  1. CI confidence interval, MJS morning joint stiffness, MTX methotrexate, NRS numeric rating scale, PRO patient-reported outcomes, RA rheumatoid arthritis
  2. aData are presented as least-squares mean unless stated otherwise
  3. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 vs. MTX